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Background: The underlying pathology and natural course of Modic changes (MC) in the vertebral body marrow
and high intensity zones (HIZs) in the annulus fibrosus is not completely clarified. These findings on magnetic
resonance imaging (MRI) have initiated different treatments with little or unclear effect. In a randomized trial
(n = 250), glucosamine sulfate (GS) had no effect on low back pain related disability. GS could still have an effect on
MC and HIZ. In this sub-study, 45 patients from the trial who had MC and/or HIZ at pre-treatment underwent
follow-up MRI. The aim was to examine the course of MC and HIZ and to compare this course between groups
treated with 6-month intake of oral GS versus placebo.
Results: Of 141 pre-treatment MC in 42 (of 45) patients, 29 (20.6%) MC in 18 patients had altered type and 14 MC
in 9 patients had altered size (decreased for 1 MC) 6-18 months later: odds ratio (OR) for type vs. size alterations 4.0;
95% confidence interval (CI) 1.2-17.7. No MC resolved. HIZ vanished from 3 of 23 discs in 3 of 21 patients with
pre-treatment HIZ. Ten new MC (all type I or I/II) occurred in 8 patients and 2 new HIZs in 2 patients. The GS group
(n = 19) and placebo group (n = 26) did not differ in proportions of MC with decreased (OR 1.6; 95% CI 0.4-6.1) or
increased type I dominance at follow-up (OR placebo:GS 2.4; 95% CI 0.6-9.7), or with increased size (OR 1.0; 95% CI
0.2-4.7). HIZ vanished from 1 of 8 discs in 1 of 8 patients in the GS group vs. 2 of 15 discs in 2 of 13 patients in the
placebo group (OR 0.8; 95% CI 0.02-12.2).
Conclusions: In this sub-group analysis of a placebo-controlled trial, the effect of GS on MC and HIZs was no
different from the effect of the placebo intervention. MC and HIZs remained mostly unchanged during the
6-18 months study period. Some short term changes did occur and MC more often altered type than size.
Trial registration: NCT00404079 at www.clinicaltrial.gov.
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Vertebral body marrow changes (Modic changes (MC))
in the lumbar vertebrae and high intensity zones (HIZs)
in the lumbar discs are frequent findings on magnetic
resonance imaging (MRI) [1]. Relationship has been sug-
gested between these findings and low back pain (LBP)
[2-5]. MC can be classified into three types (I to III)
[6,7]. Histological examination of MC type I demon-
strates disrupted and fissured endplates with regions of
degeneration, regeneration, reactive bone formation,
endplate edema and vascular granulation [7,8]. MC type
II displays endplate disruption and fatty degeneration on
histological examination and MC type III shows sclerosis
[7]. MC contain various enzymes, inflammatory media-
tors (e.g. tumor necrosis factor (TNF)) and nociceptive
nerve fibers [9-11]. Their origin is unknown, but mech-
anical stress, low grade infection secondary to disc her-
niation or some auto-immune reaction are proposed
mechanisms [12]. MC are suggested to follow a sequen-
tial pathway of a common pathological process starting
with type I followed by type II. Type I is often consid-
ered an unstable lesion that tends to alter over time,
while type II is considered more stable [7,13-18]. None-
theless, type II may change back to normal, return to
type I or develop into type III [17,19]. The stability of
type III remains uncertain [14]. Mixed types I/II and II/
III have also been identified [20,21].
An HIZ is a focal area of high signal intensity within
the posterior part of the annulus of a disc [22]. This
finding often occurs in the early stages of disc degener-
ation and may be related to a faster subsequent degener-
ation [23]. It is hypothesized to represent a collection of
mucoid fluid within fissures of the annulus or a reflec-
tion of the edge neovascularization of posterior annulus
or a healing annulus tear. These annular tears are
separations between annular fibers, separations of annu-
lar fibers from their vertebral insertions, or breaks
through these fibers in any orientation, involving one or
more layers of the annular lamellae [24]. The annulus
fibrosus is innervated by the recurrent meningeal nerve
and by the small branches from the ventral ramus of the
somatic spinal nerve [25]. HIZs may affect these nerve
endings by acid metabolites contained in the disk mater-
ial and could therefore produce LBP or referred pain
even in the absence of actual nerve root compression
[8].
The underlying pathology and natural history of MC
and HIZs is not completely clarified [12]. The identifica-
tion of these findings has led to different treatments (e.g.
antibiotic, intradiscal injection, surgery) with limited evi-
dence of effect [26,27]. In a randomized controlled trial
(RCT) of 250 chronic LBP patients, we found no effect
of glucosamine sulfate (GS) on LBP-related disability
[28]. GS may still have an effect on structural changesthat was not detected by disability evaluation within the
1-year follow-up period. GS may target IL-1β [29], a
cytokine associated with inflammation in the osteoarth-
ritic degenerative process [30]. Because MC and HIZ are
plausible markers of an osteoarthritic degenerative
process and are related to secretion of proinflammatory
mediators [31], they may contain IL-1β.
In this study, a sub-group of patients (n = 45) with MC
and/or HIZ at pre-treatment in our RCT underwent
MRI 6-18 months later [28]. The purpose was to exam-
ine the course of MC and HIZ and to compare this
course between groups treated with 6-month intake of
oral GS versus placebo. We hypothesized that GS a)
facilitates MC type conversion from the more inflamma-
tory type I to types II or III (or to normal) and prevents
switch of other MC types back to type I, b) reduces MC
size or prevents increased size, and c) causes HIZs to
disappear.
Results
All 45 included patients (mean age 45 years, range 31-
65, 20 females 44.4%) had complete MRI data at all stud-
ied endplates (n = 450) and discs (n = 225). MRI was
obtained 0-12 (median 1) months prior to the start of
the treatment period (< 50 days prior to the start of that
period in 35 of 45 patients, 77.8%). Follow-up MRI was
performed 0-12 (median 2) months after the end of the
6-month treatment period, i.e. 6-18 (median 8) months
after the pre-treatment MRI.
Pre-treatment findings in total sub-sample
Table 1 presents the frequency and type of MC pre- and
post-treatment for the 45 patients in the total sub-sam-
ple. Pre-treatment MRI showed MC at 141 (31.3%) of
450 endplates in 42 patients, most often type II (76/141,
53.9%) or type I (26/141, 18.4%; Table 1). Tables 1, 2, 3,
4 show the number/type, number of affected levels, loca-
tion and size of pre-treatment MC. MC size concerned
anteroposterior (AP) diameter and craniocaudal (CC)
extension of the MC as a proportion of the AP endplate
diameter and vertebral body height, respectively.
Pre-treatment MRI showed HIZ in 23 (10.2%) of 250
discs in 21 patients, at L3-L4 (5 of 23 discs), L4-L5 (9 of
23 discs), and L5-S1 (also 9 of 23 discs, 39.1%). HIZ
affected one disc in 20 patients and three discs in 1
patient.
Post-treatment changes in total sub-sample
At follow-up 6-18 months after their initial MRI, 21 of
all 42 patients with pre-treatment MC had altered MC
type and/or MC size. Of the 141 pre-treatment MC, 29
(20.6%) MC had altered type (Figure 1), 13 MC had
increased size (Figure 2), and 1 MC had reduced size.
Type and size alterations of MC affected 18 vs. 9 of 42
Table 1 Frequency of Modic changes (MC) in total sub-sample and by treatment group (glucosamine or placebo)
Total sub-sample (45 patients, 450 lumbar endplates)
Pre-treatment
Post-treatment No MC MC I MC I/II MC I/III MC II MC II/I MC II/III MC III MC III/I MC III/II
Total 309 26 17 2 76 11 4 2 1 2
No MC 299 299 0 0 0 0 0 0 0 0 0
MC I 25 7 16 0 0 1 0 0 0 1 0
MC I/II 27 3 7 13 0 2 2 0 0 0 0
MC I/III 1 0 0 0 1 0 0 0 0 0 0
MC II 71 0 0 1 0 69 1 0 0 0 0
MC II/I 20 0 3 3 1 4 8 1 0 0 0
MC II/III 3 0 0 0 0 0 0 3 0 0 0
MC III 0 0 0 0 0 0 0 0 0 0 0
MC III/I 0 0 0 0 0 0 0 0 0 0 0
MC III/II 4 0 0 0 0 0 0 0 2 0 2
Glucosamine group (19 patients, 190 lumbar endplates)
Pre-treatment
Post-treatment No MC MC I MC I/II MC I/III MC II MC II/I MC II/III MC III MC III/I MC III/II
Total 126 18 8 2 28 5 1 2 0 0
No MC 121 121 0 0 0 0 0 0 0 0 0
MC I 15 3 12 0 0 0 0 0 0 0 0
MC I/II 15 2 4 7 0 1 1 0 0 0 0
MC I/III 1 0 0 0 1 0 0 0 0 0 0
MC II 28 0 0 1 0 26 1 0 0 0 0
MC II/I 7 0 2 0 1 1 3 0 0 0 0
MC II/III 1 0 0 0 0 0 0 1 0 0 0
MC III 0 0 0 0 0 0 0 0 0 0 0
MC III/I 0 0 0 0 0 0 0 0 0 0 0
MC III/II 2 0 0 0 0 0 0 0 2 0 0
Placebo group (26 patients, 260 lumbar endplates)
Pre-treatment
Post-treatment No MC MC I MC I/II MC I/III MC II MC II/I MC II/III MC III MC III/I MC III/II
Total 183 8 9 0 48 6 3 0 1 2
No MC 178 178 0 0 0 0 0 0 0 0 0
MC I 10 4 4 0 0 1 0 0 0 1 0
MC I/II 12 1 3 6 0 1 1 0 0 0 0
MC I/III 0 0 0 0 0 0 0 0 0 0 0
MC II 43 0 0 0 0 43 0 0 0 0 0
MC II/I 13 0 1 3 0 3 5 1 0 0 0
MC II/III 2 0 0 0 0 0 0 2 0 0 0
MC III 0 0 0 0 0 0 0 0 0 0 0
MC III/I 0 0 0 0 0 0 0 0 0 0 0
MC III/II 2 0 0 0 0 0 0 0 0 0 2
Wilkens et al. Journal of Negative Results in BioMedicine 2012, 11:13 Page 3 of 10
http://www.jnrbm.com/content/11/1/13patients, respectively: p = 0.02; odds ratio (OR) 4.0, 95%
confidence interval (CI) 1.2-17.7. MC size did not
change at the L1-L2 endplates.
Tables 1,2, 3 show the number/type, number of affected
levels, and location of MC post-treatment. The type chan-
ged for 10 of 26 MC type I and 7 of 76 MC type II(Table 1). Four MC in 4 patients increased their AP diam-
eter. Nine MC in 9 patients had increased CC size and 1
MC had decreased CC size (Figure 3). No MC resolved
completely (to no MC). New MC occurred in 8 patients at
10 (3.2%) of 309 endplates with no pre-treatment MC.
These were 7 new MC type I at levels L5-S1 (3 MC), L3-
Table 2 Frequency of MC by number of affected
endplates per patient (45 patients, 450 lumbar
endplates)
Number of
endplates
affected by MC
Pre-treatment
frequency
of MC (any type)
Post-treatment
frequency
of MC (any type)
1 7 6
2 12 10
3 4 6
4 9 8
5 4 4
6 1 3
7 4 3
8 1 2
9 0 0
10 0 0
Total 141 151
MC, Modic changes.
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levels L4-L5 (2 MC) and L3-L4 (1 MC). Only 1 of the 10
new MC had CC size <1/10 (Figure 3).
At follow-up, HIZ had disappeared from one L5-S1
disc (Figure 4) and two L4-L5 discs in 3 patients but was
still present in 20 of 23 discs in 18 of 21 patients with
pre-treatment HIZ. New HIZ had developed in 2
patients, in the L5-S1 disc.
Comparison of changes between treatment groups
Pre-treatment, in the GS- (n = 19) and placebo group
(n = 26), 18 and 24 patients had MC and 8 and 13
patients had HIZ, respectively (Figure 5). Pre-treatment,
the GS- and placebo group were comparable in preva-
lence (per endplate), types, and sizes of MC and in
prevalence (per disc) of HIZ (p > 0.67). The frequency of
MC pre- and post-treatment differentiated by treatment
groups is presented in Table 1. Post-treatment, the GS-
and placebo group did not differ in proportions of MC
with decreased type I dominance (defined in Methods)
(OR GS:placebo 1.6, 95% CI 0.4-6.1; p = 0.46), increasedTable 3 Frequency of MC by lumbar level (45 patients, 225 le
Pre-treatment
Level Number of patients
with MC
Number of endplate
affected by MC
L1-L2 5 6
L2-L3 10 16
L3-L4 14 23
L4-L5 24 43
L5-S1 31 53
Total Not applicable 141
MC, Modic changes.type I dominance (OR placebo:GS 2.4, 95% CI 0.6-9.7;
p = 0.22), or increased MC size (OR 1.0, 95% CI 0.2-4.7;
p = 0.97).
At follow-up, HIZ had disappeared from 1 of 8 discs in
1 of 8 patients in the GS group vs. 2 of 15 discs in 2 of 13
patients in the placebo group (OR 0.8; 95% CI 0.02-12.2,
p = 0.77). One new HIZ occurred in each group.Discussion
In the present study, almost 80% of the MC and more
than 85% of the HIZs remained stable in the 6-
18 month study period. No MC resolved, but new MC,
all type I or type I/II, developed at 10 of the 450 studied
endplates. MC altered type at 29 and size at 14 of 141
affected endplates. HIZs resolved in 3 of 23 affected
discs and occurred in 2 new discs. GS did not alter the
presence or size of the MC, nor the presence of HIZ
compared to placebo.
To the authors’ knowledge, this is the first trial to test
the effect of GS on MC and HIZ and therefore no dir-
ectly comparable data exists. Other treatments of
patients with LBP and findings of MC or HIZ have been
tested for clinical effect but not for effect on MC or
HIZ. An uncontrolled pilot study found clinical effect of
antibiotics in patients with LBP and MC type I [26]. An-
other study of 120 patients with LBP and MC type I or
II indicated short-term clinical effect of intradiscal ster-
oid injection [27]. LBP patients with HIZ have been
treated with other interventions like intradiscal electro-
thermal therapy and intradiscal radiofrequency thermo-
coagulation without clear conclusions [32-34].
Several reasons may explain the lack of difference in
effect on MC and HIZ between GS- and placebo group.
GS may be ineffective as modifier of the potential mar-
kers of inflammatory pain and secretion of proinflamma-
tory mediators associated with MC and HIZ. Previous
research has demonstrated the inability of GS to reduce
LBP or LBP-related disability [28]. GS may slow down
the destruction of cartilage in osteoarthritis (OA) by
inhibiting the pro-inflammatory IL-1β [29]. IL-1β isvels, 2 endplates per level)
Post-treatment
s Number of patients
with MC
Number of endplates
affected by MC
5 6
11 17
17 27
26 45
34 56
Not applicable 151
Table 4 Pre-treatment frequency of Modic changes by
size (45 patients, 450 lumbar endplates)
Modic changes type I (26 endplates)
AP diameter
CC extension <1/4 1/4 -1/2 >1/2 Total
<1/10 (minimal / small dots) 1 1 1 3
<1/4 1 4 4 9
1/4 - 1/2 0 1 7 8
>1/2 0 0 6 6
Modic changes type I/II (17 endplates)
AP diameter
CC extension <1/4 1/4 -1/2 >1/2 Total
<1/10 (minimal / small dots) 0 1 1 2
<1/4 0 1 4 5
1/4 - 1/2 0 1 4 5
>1/2 0 0 5 5
Modic changes type II (76 endplates)
AP diameter
CC extension <1/4 1/4 -1/2 >1/2 Total
<1/10 (minimal / small dots) 12 3 1 16
<1/4 11 15 15 41
1/4 - 1/2 0 3 11 14
>1/2 0 0 5 5
Modic changes type II/I (11 endplates)
AP diameter
CC extension <1/4 1/4 -1/2 >1/2 Total
<1/10 (minimal / small dots) 0 0 0 0
<1/4 0 2 1 3
1/4 - 1/2 0 0 7 7
>1/2 0 0 1 1
Modic changes all other types (I/III, II/III, III, III/I or III/II)
(11 endplates)
AP diameter
CC extension <1/4 1/4 -1/2 >1/2 Total
<1/10 (minimal / small dots) 0 0 0 0
<1/4 0 0 1 1
1/4 - 1/2 0 0 3 3
>1/2 0 0 7 7
AP diameter, maximal anteroposterior diameter of Modic changes as a
proportion of the anteroposterior endplate diameter; CC extension, maximal
craniocaudal extension of Modic changes as a proportion of the vertebral
body height.
A B
DC
Figure 1 Altered type of Modic changes. Initial (A-B) and follow-
up (C-D) sagittal magnetic resonance images of one patient. Type I
Modic changes (arrows; high signal on T2-weigthed image A, low
signal on T1-weighted image B) alters to type II (high signal on T2-
and T1-weighted images C and D; images not shown revealed
alteration to type II/I).
A B
Figure 2 Increased size of Modic changes. Initial (A) and follow-
up (B) sagittal T2-weigthed magnetic resonance images of one
patient. Modic changes at L3/L4 increase in craniocaudal extent
from <1/4 to >1/2 of the vertebral body height from image A to
image B (arrows).
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ever, opposite to our assumptions, IL-1 β may not be
pathologically relevant for MC or HIZ. Furthermore, 6-
month glucosamine exposure may be too short time
period to impact an area with limited direct blood sup-
ply. It is also possible that GS does not reach the target
area because of either low concentration in the blood
stream or insufficient blood supply to the lumbar verte-
bras and discs. However, the lack of demonstrable
Craniocaudal (CC) size of Modic changes (MC)
NoMC < 1/10 < 1/4 1/4 – 1/2 > 1/2
Pre Post Pre Post Pre Post Pre Post Pre Post
NoMC 96.8%
299
< 1/10
0.3%
1 90.5%
19
< 1/4
1.9%
6
9.5%
2 89.8%
53
1/4 – 1/2
1.0%
3
8.5%
5 97.3%
36 4.2%
1
>1/2
1.7%
1
2.7%
1 95.8%
23
Figure 3 Pre- and post-treatment craniocaudal size of Modic changes at 450 endplates in 45 patients. Arrows indicate size development.
Numbers are percentages and numbers of endplates.
D
B
C
A
Figure 4 Resolving high intensity zone. Initial (A-B) and follow-up
(C-D) T2-weighted magnetic resonance images of one patient.
Image plane B is marked on A and image plane D is marked on C
(stippled lines). High intensity zone in the L5/S1 disc on initial
sagittal (A) and axial (B) images (arrows) is resolved on later sagittal
(C) and axial (D) images.
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larger sample of MC and especially of HIZs would have
made it easier to detect any smaller effect of GS on the
rather slow natural course of these findings.
No MC vanished during the study period. MC are not
necessarily everlasting as population research has
reported resolution of MC [36]. However, the research is
conflicting as others have found limited, or no evidence
of resolution of established MC [17,19]. Different type of
sample (general population versus LBP patients) and
sample size (> 300 versus < 50 patients) may explain
some of the discrepancy [17,19,36].
The development of 10 new MC (in 8 of 45 patients)
confirmed that MC often surface in patients with LBP
[36]. All new MC were predominantly type I, which may
support the notion that MC type I is the start point for
the MC evolution [12]. Several MC, more type I than
type II converted into a different type, indicating that
MC are viable to change in as short term as 6 months to
1 year. Previous research has shown that MC may con-
vert over 3 to 5 years after discectomy [37]. In addition,
any type of MC may be more prone to switch between
types than previously thought [7].
Our data confirmed that MC type I is less stable than
MC type II [13,17]. However, almost 80% of the MC did
not change, which is also comparable with previous
studies [20]. The MC size in terms of AP diameter and
CC extension was more stable than the type of MC. It is
noteworthy that also small MC had stable extension and
did not tend to come and go. This was different from
previous results that were not based on direct compari-
son of initial and follow-up images [36]. The most
Figure 5 Current sub-sample and pre-treatment findings by treatment group. Shown are numbers of Modic changes (MC) and of discs
with high intensity zone (HIZ) by treatment group (glukosamine or placebo) in the current sub-sample of 45 patients with MC and / or HIZ from
a trial of 250 chronic low back pain patients; n denotes number of patients.
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L4-L5 endplates, which is in line with previous reports [14].
The most common locations for HIZ were also L5-
S1 and L4-5, which follows previous reports [38].
More than 85% of the discs with HIZ remained
stable throughout the study, which is also in line
with earlier research [39]. On the other hand, HIZ
was in most cases (more than 95%) present at one
disc space only. The occurrence of HIZ at one level
only is also comparable with past research [38-42].
The present study has several strengths. It included a
potentially important and distinct sub-group of LBP suf-
ferers with MC and HIZ among the greater population
of unspecific, longstanding low back pain. Two inde-
pendent readers rated the MRIs using established criteria, a
third independent reader resolved any disagreements, and
all readers were blinded to age, gender, treatment and
clinical information. Changes in MRI findings were rated
by comparing initial and follow up images. This approach
reflects clinical practice and is optimal for rating changes in
MRI findings over time [43,44]. Assessment of follow-up
images blinded to the initial images, may introduce
unwanted variation in the rating of any alterations.
Study limitations require attention. This sub-study of
the original RCT should be considered exploratory in na-
ture. It had small sample size and was not based on a sep-
arate power calculation. The wide time range (more than
50 days) between some of the pre-treatment MRIs (10
patients) and the start of the treatment may have clouded
potential alterations in MC and HIZ due to GS. Further-
more, all readers knew that all of the images were from
patients with MC and/or HIZ, and this knowledge may
have influenced the evaluation. However, an abundant
number of normal as well as abnormal spinal levels were
evaluated. Slight variability in MRI technique introducedheterogeneity, but reflects clinical practice. We focused on
two MRI abnormalities only and did not address other po-
tentially relevant degenerative findings like disc- or facet
degeneration, discs bulges or disc herniations. The loca-
tion of MC within the endplate was not assessed. HIZ was
not confirmed using discography and we did not apply
contrast enhanced T1-weighted MRI, which may be more
sensitive to detect HIZ than T2-weighted MRI [45,46].
However, Munter et al found no increased sensitivity to
detect HIZ with contrast enhancement [47]. New bio-
chemical MRI methods exist for evaluating the interverte-
bral disc, such as T2 mapping, T2* mapping and diffusion
weighted imaging [48-50]. These methods may be more
sensitive to changes under therapy than the morphological
MRI techniques used in our study.
Conclusions
GS had no clear effect on MC or HIZ in this group of
LBP patients. Regardless of intervention, most findings
of MC and HIZ remained stable during the 6-18 months
study period. However, short term changes in MC and
HIZs did occur. Based on this study, it is likely that the
MC development starts with type I, that MC more often
alter type than size, and that small MC may be equally
stable as larger MC.
Methods
This study included a sub-sample of 45 patients who
had any type of MC and/or HIZ on lumbar MRI at in-
clusion in a prospective double-blind RCT comparing
GS to placebo as treatment for chronic LBP [28]
(Figure 5). The original RCT included 250 patients and
was registered at www.clinicaltrial.gov under the identifier
NCT00404079. The study was carried out in compliance
with the Helsinki Declaration and it was approved by The
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for medical research ethics in east Norway and the Data In-
spectorate. Written informed consent was obtained from
all participants prior to enrollment.
Eligibility criteria and intervention
The 45 patients were recruited from 12.6.2007 to
16.7.2008. They were asked to participate in the present
study by undergoing follow-up MRI and all agreed. As
detailed elsewhere [28], inclusion criteria in the original
trial were age > 25 years, primary complaint of nonspecific
LBP, LBP for at least six months, and summed score of at
least 3 out of 24 points on Roland Morris Disability Ques-
tionnaire. Exclusion criteria included worse leg pain than
back pain, symptomatic disc herniation or spinal stenosis,
previous lumbar fracture or surgery, pregnancy or breast-
feeding, seafood allergy, ongoing psychiatric or somatic
disease potentially influencing their pain and use of any
type of glucosamine 1 year prior to enrollment. The inter-
vention consisted of three capsules (500 mg each) of GS
or placebo every day for six months. Initiation of new
therapies was not permitted during the intervention
period, but the patients were allowed to maintain estab-
lished management and/or use rescue medication.
MRI evaluation
The 45 patients underwent 1.5 T MRI at different imaging
institutions. Follow-up MRI was taken from 1.2.2008 to
13.5.2009. The same scanner was used pre- and post-
treatment for 21 (46.7%) patients. All 90 MRIs included
sagittal T1- and T2-weighted scans of the whole lumbar
spine and axial T1- or T2-weighted scans of at least the
three lower lumbar levels. Sagittal T1-weighted images
were turbo spin echo (TSE) images (repetition time (TR) /
echo time (TE), 400-911 ms / 8-14 ms) or, for 10 pre- and
8 post-treatment MRIs, fast fluid-attenuated inversion-re-
covery images (TR / TE, 1989-1999 ms / 20 ms). Sagittal
T2-weighted images were TSE images (TR / TE, 2500-
5930 ms / 89-125 ms) or, for 11 post-treatment MRIs,
spatial and chemical shift encoded excitation images
(1500 ms / 251 ms).
Two observers, blinded to clinical data and treatment
group, independently rated MC and HIZs for the 45
pre-treatment MRIs, presented de-identified in a ran-
dom order. The observers were an experienced radiolo-
gist (AE) and a chiropractor (PW) experienced in
evaluating MC and HIZ. In two pilot studies, they had
interpreted and discussed 20 lumbar MRIs from another
study to improve their ratings of MC and HIZ. The MC
classification has demonstrated to be reliable to apply
for observers of varying experience [21,51,52]. In our
study, interobserver agreement was good to very good
for MC (yes/no, kappa 0.69-1.00) and fair to good for
HIZ (yes/no, kappa 0.35-0.73) at L3/L4, L4/L5 and L5/S1 on pre-treatment MRI (kappa not calculated at L1/L2
or L2/L3 due to low prevalence of “yes” [53]).
MC were evaluated at each of the ten endplates L1-S1.
They were graded into MC type 0 (no MC), I (hypoin-
tense T1-signal and hyperintense T2-signal), II (hyperin-
tense T1-signal and iso- or hyperintense T2-signal), III
(hypointense T1-signal and hypointense T2-signal) and
mixed types (e.g. I/II, listing the most extensive type first)
[7,8,24,54]. Maximal anteroposterior (AP) diameter of
the MC was recorded as <1/4, ¼-1/2 or >1/2 of the AP
endplate diameter. Maximal craniocaudal (CC) extent of
the MC was recorded as <1/10 (minimal/small dots), <1/
4, ¼-1/2 or >1/2 of the vertebral body height [51]. HIZ
was identified on T2-weighted images as an area of high
signal intensity in the posterior annulus fibrosus that was
brighter than the nucleus pulposus and was surrounded
superiorly, inferiorly and anteriorly by the low-intensity
(black) signal of the annulus [55]. HIZ was noted as
present or not present at each of the five disc levels L1-
S1. Anterior annular fissure was not assessed.
In all cases of disagreement between the two observers
a third observer (a second experienced radiologist, LB)
independently examined the images. The majority view
(or median rating for size of MC) was taken as the con-
clusive rating. If all three observers disagreed on type of
MC they re-evaluated the images in consensus and
reported a shared conclusive result. The conclusive rat-
ing was first determined for all pre-treatment scans and
was noted on a form. Then, on separate copies of this
form observers 1 and 2 independently (and still blinded
to clinical data and treatment group) reported changes
in rating from pre- to post-treatment MRI based on dir-
ect comparison of the two sets of images. Again, in all
cases of disagreement a conclusive majority or consen-
sus rating was achieved with the observer 3.
MC and HIZ outcomes
The outcomes used to test the effect of GS were the pro-
portions of a) MC with decreased or increased MC type
I dominance post-treatment, b) MC with decreased or
increased size (at least one category change in AP diam-
eter and/or CC extent), and c) discs with HIZ where
HIZ had disappeared. The order of more to less MC
type I dominance was defined by the following four
combined MC type categories: I, I/II-III, II-III/I, all other
types.
Statistical analysis
The frequency of MC and HIZ at pre- and post-
treatment MRI and the frequency of alterations of MC
and HIZ from pre-treatment to post-treatment were cal-
culated with frequency tables and cross-tabulations. Pro-
portions of patients with altered type vs. altered size of
MC were compared using McNemar’s test and by
Wilkens et al. Journal of Negative Results in BioMedicine 2012, 11:13 Page 9 of 10
http://www.jnrbm.com/content/11/1/13computing OR with mid-P exact 95% CI [56]. Propor-
tions of changed MC were compared between treatment
groups by calculating ORs with 95% CIs adjusted for
intracluster correlations between different pre-treatment
MC in the same patient (Rao-Scott method) [57]. Since
only one patient had HIZ at more than one disc (i.e.
clustered data), proportions of patients (not discs) with
vanished HIZ were compared using OR with mid-P
exact 95% CI. All p-values are 2-sided and the signifi-
cance level was 5%. Analyses were performed with SPSS
version 18.0 for Windows (SPSS, Inc., Chicago, Illinois)
and WINPEPI version 11.22 (http://www.brixtonhealth.
com/pepi4windows.html).
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